Intract Pharma

Executive Summary

Intract Pharma is a UK-based biotechnology company pioneering advanced oral drug delivery technologies for biologic therapeutics, including monoclonal antibodies. Founded in 2006 and headquartered in Nottingham, the company aims to transform patient care by enabling oral administration of drugs traditionally given via injection. Its proprietary platforms, Soteria® and Phloral®, are designed for precise, targeted delivery within the gastrointestinal tract, potentially improving patient compliance and reducing healthcare costs. Intract is currently in the pre-clinical stage, with a focus on developing its technology for a range of therapeutic indications. The company's innovative approach addresses a critical unmet need in biologics delivery, which could unlock significant market opportunities if successfully translated into clinical candidates.

Upcoming Catalysts (preview)

• Q3 2026Initiation of first-in-human clinical trial for lead candidate40% success
• Q1 2027Strategic partnership with a major pharmaceutical company for platform licensing50% success
• Q2 2026Completion of Series A or government grant to fund pipeline advancement70% success